AI Science Tracker

EVEscape: predicting viral variants before they emerge

Harvard Medical School; and University of Oxford · 11 Oct 2023 · biology

Discovery

EVEscape: predicting viral variants before they emerge

Starting from January 2020, the tool predicted SARS-CoV-2 mutations with accuracy similar to experimental antibody-binding assays and ranked their prevalence better; it generalizes to HIV and influenza. Retrospective validation; prospective performance is not reported.

Technology: EVEscape

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: EVEscape was trained only on pre-2020 sequences and compared against high-throughput experimental scans of SARS-CoV-2 variation that later emerged, a retrospective validation; prospective performance is not reported.
  • Still unknown: The abstract states no limitations; the page says testing on Lassa and Nipah is ongoing and vaccine or therapy use against future variants is a future application.
  • AI role: A deep learning model of historical viral sequences, combined with biophysical and structural information, scored the escape potential of mutations.

Evidence sources: https://hms.harvard.edu/news/ai-tool-can-help-forecast-viral-outbreaks · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06617-0&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 245 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.